Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2010 May 24:10:231.
doi: 10.1186/1471-2407-10-231.

Improved survival for non-Hodgkin lymphoma patients in New South Wales, Australia

Xue Q Yu  1 , Wendy H Chen, Dianne L O'Connell
Affiliations

Improved survival for non-Hodgkin lymphoma patients in New South Wales, Australia

Xue Q Yu et al. BMC Cancer. .

Abstract

Background: We evaluated if the survival benefit of adding rituximab to standard chemotherapy for non-Hodgkin lymphoma (NHL) observed in clinical trials has been experienced by an Australian NHL patient population.

Methods: NHL cases diagnosed in 1985-2004 in New South Wales (NSW) were followed-up to the end of 2004. Rituximab prescription data were obtained from Medicare Australia. Using a Poisson regression model adjusted for age group, sex, NHL subtype and time period (1990-1994, 1995-1999 and 2000-2004), we estimated excess risk of death after a diagnosis of NHL. To give context to the survival trend, trends in incidence and mortality were also estimated.

Results: Compared with 1990-1994, after adjusting for age, sex and NHL subtype the relative excess risk of death was significantly lower (p < 0.0001) in 1995-1999 (0.89) and 2000-2004 (0.74). A sharp fall in mortality was observed from 2000 to 2004 (annual percentage change (APC) = -4.7, p = 0.009), while a small but significant rise in incidence was seen from 1990 to 2004 (APC = 0.5, p = 0.01). The number of times rituximab was dispensed in NSW increased rapidly from 1274 in 1999 to 9250 in 2004.

Conclusion: It is likely that some benefit of adding rituximab to the standard chemotherapy for NHL has been experienced at the population level.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Trends in five-year relative survival for NHL by age group at diagnosis, NSW Australia, 1990-2004.
Figure 2
Figure 2
Trends in five-year relative survival for NHL by histological subtype, NSW Australia, 1990-2004.
Figure 3
Figure 3
Number of times rituximab was dispensed for treatment of NHL, NSW Australia, 1999-2004.
See this image and copyright information in PMC

References

    1. Molina A. A decade of rituximab: improving survival outcomes in non-Hodgkin's lymphoma. Annu Rev Med. 2008;59:237–250. doi: 10.1146/annurev.med.59.060906.220345. - DOI - PubMed
    1. Fisher RI, Gaynor ER, Dahlberg S, Oken MM, Grogan TM, Mize EM, Glick JH, Coltman CA Jr, Miller TP. Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma. N Engl J Med. 1993;328(14):1002–1006. doi: 10.1056/NEJM199304083281404. - DOI - PubMed
    1. Australian Drug Evaluation Committee - 197th meeting recommendations. http://www.tga.gov.au/docs/html/adec/adec0197.htm
    1. Australian Drug Evaluation Committee - 220th meeting recommendations. http://www.tga.gov.au/docs/html/adec/adec0220.htm
    1. Tracey E, Alam N, Chen W, Bishop J. Cancer in New South Wales: Incidence and Mortality 2006. Sydney: Cancer Institute NSW; 2008.

Publication types

MeSH terms

Substances

LinkOut - more resources